These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 23214297)

  • 21. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
    Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
    Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA topoisomerase IIalpha in multiple myeloma: a marker of cell proliferation and not drug resistance.
    Wilson CS; Medeiros LJ; Lai R; Butch AW; McCourty A; Kelly K; Brynes RK
    Mod Pathol; 2001 Sep; 14(9):886-91. PubMed ID: 11557785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of p53 and selected proliferative markers (Ki-67, MCM3, PCNA, and topoisomerase IIα) in borderline ovarian tumors: Correlation with clinicopathological features.
    Ciepliński K; Jóźwik M; Semczuk-Sikora A; Gogacz M; Lewkowicz D; Ignatov A; Semczuk A
    Histol Histopathol; 2018 Feb; 33(2):171-179. PubMed ID: 28493257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity.
    Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J
    Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
    Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
    Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
    Hengstler JG; Lange J; Kett A; Dornhöfer N; Meinert R; Arand M; Knapstein PG; Becker R; Oesch F; Tanner B
    Cancer Res; 1999 Jul; 59(13):3206-14. PubMed ID: 10397267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Topo IIα gene alterations correlated with survival in patients with diffuse large B-cell lymphoma.
    Chen Z; Wang J; Zhang H; Liu D; Li Y; Xu Y; Tan D; Chen D; Zhao X; Wang G
    Eur J Clin Invest; 2012 Mar; 42(3):310-20. PubMed ID: 21880040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase IIalpha, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow.
    Schindlbeck C; Hantschmann P; Zerzer M; Jahns B; Rjosk D; Janni W; Rack B; Sommer H; Friese K
    Int J Gynecol Cancer; 2007; 17(5):1047-55. PubMed ID: 17433065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Topoisomerase IIalpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia.
    Uggla B; Tina E; Nahi H; Paul C; Höglund M; Sirsjö A; Tidefelt U
    Int J Oncol; 2007 Jul; 31(1):153-60. PubMed ID: 17549416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of topoisomerase I/topoisomerase IIalpha status in esophageal cancer.
    Hanagiri T; Ono K; Kuwata T; Takenaka M; Oka S; Chikaishi Y; Shigematsu Y; Nagata Y; Shimokawa H; Nakagawa M; Uramoto H; So T; Tanaka F
    J UOEH; 2011 Sep; 33(3):205-16. PubMed ID: 21913377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topoisomerase IIalpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome.
    Schrader C; Meusers P; Brittinger G; Teymoortash A; Siebmann JU; Janssen D; Parwaresch R; Tiemann M
    Leukemia; 2004 Jul; 18(7):1200-6. PubMed ID: 15116121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The value of expression of EGFR, telomerase and topoisomerase IIα in malignant effusion smears before and after chemotherapy.
    Koutsionasios J; Diab A; Athanasiadou AM; Petrakakou E; Marinos G; Kalyteraki J; Athanasiadou P; Konstantopoulos K
    J BUON; 2012; 17(3):554-9. PubMed ID: 23033298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA topoisomerase I and IIalpha expression in penile carcinomas: assessing potential tumour chemosensitivity.
    Berney DM; Stankiewicz E; Adlan AM; Kudahetti S; Biedrzycki OJ; Hadway P; Watkin N; Corbishley C
    BJU Int; 2008 Sep; 102(8):1040-4. PubMed ID: 18489530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures.
    Du Y; Zhou Q; Yin W; Zhou L; Di G; Shen Z; Shao Z; Lu J
    Breast Cancer Res Treat; 2011 Oct; 129(3):839-48. PubMed ID: 21809115
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Expression and significance of MRP, GST-pi, Topo IIalpha, and LRP in gastric carcinoma].
    Yu DQ; Yi YF
    Ai Zheng; 2003 May; 22(5):496-9. PubMed ID: 12753710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer.
    Nakopoulou L; Lazaris AC; Kavantzas N; Alexandrou P; Athanassiadou P; Keramopoulos A; Davaris P
    Pathobiology; 2000; 68(3):137-43. PubMed ID: 11174071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topoisomerase IIalpha expression in ductal carcinoma in situ of the breast: a preliminary study.
    Shpitz B; Bomstein Y; Zehavi T; Bernheim J; Liverant S; Kaufman Z; Buklan G; Klein E
    Hum Pathol; 2000 Oct; 31(10):1249-54. PubMed ID: 11070118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemical staining of DNA topoisomerase IIalpha in human gliomas.
    Taniguchi K; Wakabayashi T; Yoshida T; Mizuno M; Yoshikawa K; Kikuchi A; Nakashima N; Yoshida J
    J Neurosurg; 1999 Sep; 91(3):477-82. PubMed ID: 10470824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas.
    Sundov D; Caric A; Mrklic I; Gugic D; Capkun V; Hofman ID; Mise BP; Tomic S
    Diagn Pathol; 2013 Feb; 8():21. PubMed ID: 23388101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.